|Filed Under:||Mental Health / Alzheimer's|
|Posts on Regator:||233|
|Posts / Week:||3.6|
|Archived Since:||September 12, 2016|
Researchers report on the first large-scale longitudinal imaging study to evaluate BACE1 inhibition with micro-PET in mouse models of Alzheimer's disease. PET imaging has been established as an excellent identifier of the amyloid plaque and tau tangles that characterize Alzheimer's disease. Now it is proving to be an effective way to gauge treatment effectiveness.
Hospitals are making mini brains from human stem cells, putting researchers on a fast track to repair the nervous system after injury or disease of the brain and spinal cord. Researchers have developed a new system to reduce the time...Show More Summary
A new small-molecule drug can restore brain function and memory in a mouse model of Alzheimer's disease. The molecule, called anle138b, works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envision that this drug could be used to treat Alzheimer's and other neurodegenerative diseases such as Parkinson's and ALS.
Making an AD mouse model that incorporates both A-beta and tau pathologies in a more AD-relevant context has been greatly sought after but difficult to accomplish. Now, researchers have done that and it's a big step for AD research, which will allow for new therapies to be tested in a more realistic context.
Patients with the RBD sleep behavior disorder lack dopamine and have a form of inflammation of the brain, researchers have found. This means that they are at risk of developing Parkinson's disease or dementia when they grow older.
Full results from a second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, has been released by researchers.
Investigators have discovered dozens of new genetic variations associated with a person's general cognitive ability. While profiling cognitive ability, researchers also discovered a genetic overlap with longevity.
Alzheimer's disease is caused by tangles in the brain made up of malfunctioning aggregated Tau proteins. Scientists have discovered a new toxic form of Tau that forms as a result of its interaction with cell membranes. The research provides novel insights into possible mechanisms by which this protein moves in the brain and kills neurons.
Scientists have concluded that developing dementia or Alzheimer's disease (the most common form of dementia) did not appear to be linked to taking proton pump inhibitors (PPIs).
Using ‘Raman’ optical technology, scientists can now produce images of brain tissue that is affected by Alzheimer’s disease. The images include the surrounding areas, already showing changes.
Humans have roughly as many bacterial cells in their bodies as human cells, and most of those bacteria live in the gut. New research released today reveals links between the gut microbiome -- the population of microorganisms living in...Show More Summary
Advanced clinical trials are underway for at least 10 investigational therapies that have shown promise in slowing or blocking development of Alzheimer's disease, creating hope that a preventive strategy may be in reach. But a new study warns that the U.S. Show More Summary
The number of people with Parkinson's disease will soon grow to pandemic proportions, research concludes. In a new article, researchers argue that the medical community must be mobilized to respond to this impending public health threat.
Scientists have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study shows that membralin regulates the cell's machinery for producing beta-amyloid (or amyloid beta), the protein that causes neurons to die in Alzheimer's disease.
Researchers have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery may also provide a means of homing drugs to diseased areas of the brain to treat AD, Parkinson's disease, as well as glioblastoma, brain injuries and stroke.
Scientists have disproved a decades-old orthodoxy: cerebrospinal fluid does not leave the cranial cavity via blood vessels, but instead through the lymphatic system. This finding has far-reaching implications in new treatments for dementia.
Researchers have discovered a new type of transition in protein folding: amyloid crystals formed from amyloid fibrils by a decrease in energy. The crystals are even more stable than the fibrils, which are responsible for a number of serious neurodegenerative diseases in humans.
Vision scientists have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
Researchers have identified a new protective function for a brain protein genetically linked to Alzheimer's. The findings could inform novel treatment strategies to combat neurodegenerative diseases.
Treatment with a neuroprotective compound that saves brain cells from dying also prevents the development of depression-like behavior and the later onset of memory and learning problems in a rat model of Alzheimer's disease, according to new research. Show More Summary